A5108062434- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- 14-3-3 protein interactions
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Foreign Body Medical Cases
- Sarcoma Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Neonatal Respiratory Health Research
- Frailty in Older Adults
- Family and Patient Care in Intensive Care Units
- Intraperitoneal and Appendiceal Malignancies
- Estrogen and related hormone effects
- Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
- Peptidase Inhibition and Analysis
- Nutrition and Health in Aging
- Infant Development and Preterm Care
- Cancer Genomics and Diagnostics
- Tracheal and airway disorders
- Veterinary Oncology Research
- Teratomas and Epidermoid Cysts
- Ferroptosis and cancer prognosis
Dartmouth Institute for Health Policy and Clinical Practice
2022
Medizinische Hochschule Hannover
2018
Tokyo Metropolitan Komagome Hospital
2011
Roche (Switzerland)
2011
Universitair Ziekenhuis Leuven
2011
Klinikum Braunschweig
2011
Queen Elizabeth Hospital
2011
Seoul National University
2011
Bronchoscopy is an established procedure routinely used by pediatric pulmonologists. Despite its frequent application, data on complications and specific risk factors are scarce sometimes conflicting.The aim of this study was to evaluate frequency severity clearly defined bronchoscopy in children that occur both during after the procedure, identify potential factors.A retrospective single-center analysis 670 elective bronchoscopies 522 aged 0-17 years time period 2008-2012 performed....
<h3>Importance</h3> Birth at hospitals with an appropriate level of neonatal intensive care units is associated better outcomes. The primary sources for information about hospital unit levels prospective parents, referring physicians, and the public are websites, but accuracy capacity unclear. <h3>Objective</h3> To determine if websites accurately report capabilities intermediate (ie, II) units, which intended newborns low to moderate illness or stabilization prior transfer. <h3>Design,...
e13555 Background: Gallbladder toxicity, including cholecystitis, has been seen in studies of motesanib, an orally administered small-molecule antagonist VEGFRs 1, 2 and 3; PDGFR; Kit. We assessed effects motesanib on gallbladder size function pts with advanced solid tumors. Methods: Pts (≥18 y) metastatic tumors ineligible for or having progressed standard-of-care therapies, ECOG ≤2, no history cholecystitis biliary disease were randomized 2:1:1 to receive 3-wk cycles 125 mg once daily (Arm...
3560 Background: Motesanib diphosphate is an oral investigational, highly selective inhibitor of VEGF, PDGF and Kit receptors. In advanced cancer, inhibition EGFR VEGFR, with or without chemotherapy, has shown promising activity. Methods: Ongoing, open-label, dose-finding, phase 1b study motesanib plus G E in pts solid tumors. Objectives are to establish the maximum-tolerated dose (MTD), safety, PK tumor response (Q12W). Pts had documented tumors, ECOG 0–2 no prior G, anti-VEGF therapy....
e21029